These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31778714)

  • 21. TPA induction leads to a Th17-like response in transgenic K14/VEGF mice: a novel in vivo screening model of psoriasis.
    Hvid H; Teige I; Kvist PH; Svensson L; Kemp K
    Int Immunol; 2008 Aug; 20(8):1097-106. PubMed ID: 18579711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Adalimumab on Gene Expression Profiles of Psoriatic Skin and Blood.
    Chow M; Lai K; Ahn R; Gupta R; Arron S; Liao W
    J Drugs Dermatol; 2016 Aug; 15(8):988-94. PubMed ID: 27538000
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-tumor necrosis factor-alpha therapy improves endothelial function and arterial stiffness in patients with moderate to severe psoriasis: A 6-month prospective study.
    Pina T; Corrales A; Lopez-Mejias R; Armesto S; Gonzalez-Lopez MA; Gómez-Acebo I; Ubilla B; Remuzgo-Martínez S; Gonzalez-Vela MC; Blanco R; Hernández JL; Llorca J; Gonzalez-Gay MA
    J Dermatol; 2016 Nov; 43(11):1267-1272. PubMed ID: 27062420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis.
    Wolk K; Witte E; Warszawska K; Schulze-Tanzil G; Witte K; Philipp S; Kunz S; Döcke WD; Asadullah K; Volk HD; Sterry W; Sabat R
    Eur J Immunol; 2009 Dec; 39(12):3570-81. PubMed ID: 19830738
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting tumor necrosis factor alpha in psoriasis and psoriatic arthritis.
    Fantuzzi F; Del Giglio M; Gisondi P; Girolomoni G
    Expert Opin Ther Targets; 2008 Sep; 12(9):1085-96. PubMed ID: 18694376
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequency of thrombocytopenia in psoriasis patients treated with tumor necrosis factor-a inhibitors.
    Chen M; Holland MJ; Mir MR; Wong MG; Kelley BP; Grim KD; Bhuchar SS; Hsu S
    J Drugs Dermatol; 2011 Mar; 10(3):280-4. PubMed ID: 21369645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual role of anti-TNF therapy: enhancement of TCR-mediated T cell activation in peripheral blood and inhibition of inflammation in target tissues.
    Bosè F; Raeli L; Garutti C; Frigerio E; Cozzi A; Crimi M; Caprioli F; Scavelli R; Altomare G; Geginat J; Abrignani S; Reali E
    Clin Immunol; 2011 May; 139(2):164-76. PubMed ID: 21334981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-TNF-α therapy improves insulin sensitivity in non-diabetic patients with psoriasis: a 6-month prospective study.
    Pina T; Armesto S; Lopez-Mejias R; Genre F; Ubilla B; Gonzalez-Lopez MA; Gonzalez-Vela MC; Corrales A; Blanco R; Garcia-Unzueta MT; Hernandez JL; Llorca J; Gonzalez-Gay MA
    J Eur Acad Dermatol Venereol; 2015 Jul; 29(7):1325-30. PubMed ID: 25353352
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Etanercept suppresses regenerative hyperplasia in psoriasis by acutely downregulating epidermal expression of interleukin (IL)-19, IL-20 and IL-24.
    Wang F; Smith N; Maier L; Xia W; Hammerberg C; Chubb H; Chen C; Riblett M; Johnston A; Gudjonsson JE; Helfrich Y; Kang S; Fisher GJ; Voorhees JJ
    Br J Dermatol; 2012 Jul; 167(1):92-102. PubMed ID: 22458549
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and mean platelet volume in Japanese patients with psoriasis and psoriatic arthritis: Response to therapy with biologics.
    Asahina A; Kubo N; Umezawa Y; Honda H; Yanaba K; Nakagawa H
    J Dermatol; 2017 Oct; 44(10):1112-1121. PubMed ID: 28493493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of TNF-alpha inhibitors on circulating Th17 cells in patients affected by severe psoriasis.
    Piaserico S; Sandini E; Saldan A; Abate D
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S73-6. PubMed ID: 25381985
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment.
    Tillack C; Ehmann LM; Friedrich M; Laubender RP; Papay P; Vogelsang H; Stallhofer J; Beigel F; Bedynek A; Wetzke M; Maier H; Koburger M; Wagner J; Glas J; Diegelmann J; Koglin S; Dombrowski Y; Schauber J; Wollenberg A; Brand S
    Gut; 2014 Apr; 63(4):567-77. PubMed ID: 23468464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-IL-17A and IL-23p19 antibodies but not anti-TNFα antibody induce expansion of regulatory T cells and restoration of their suppressive function in imiquimod-induced psoriasiform dermatitis.
    Shimizu T; Kamata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
    J Dermatol Sci; 2019 Sep; 95(3):90-98. PubMed ID: 31362906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE.
    Ortonne JP; Chimenti S; Reich K; Gniadecki R; Sprøgel P; Unnebrink K; Kupper H; Goldblum O; Thaçi D
    J Eur Acad Dermatol Venereol; 2011 Sep; 25(9):1012-20. PubMed ID: 21214631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reflectance confocal microscopy for plaque psoriasis therapeutic follow-up during an anti-TNF-α monoclonal antibody: an observational multicenter study.
    Ardigò M; Agozzino M; Longo C; Lallas A; Di Lernia V; Fabiano A; Conti A; Sperduti I; Argenziano G; Berardesca E; Pellacani G
    J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2363-8. PubMed ID: 26299420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of anti-TNF-α agents on circulating endothelial-derived and platelet-derived microparticles in psoriasis.
    Pelletier F; Garnache-Ottou F; Biichlé S; Vivot A; Humbert P; Saas P; Seillès E; Aubin F
    Exp Dermatol; 2014 Dec; 23(12):924-5. PubMed ID: 25255926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Langerhans cell markers CD1a and CD207 are the most rapidly responding genes in lesional psoriatic skin following adalimumab treatment.
    Raaby L; Rosada C; Langkilde A; Lauridsen KL; Vinter H; Ommen P; Kjellerup RB; Johansen C; Iversen L
    Exp Dermatol; 2017 Sep; 26(9):804-810. PubMed ID: 28109175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)-α level and the efficacy of TNF-inhibitor therapy in psoriasis.
    Kui R; Gál B; Gaál M; Kiss M; Kemény L; Gyulai R
    J Dermatol; 2016 Sep; 43(9):1018-23. PubMed ID: 26892625
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lowering Interleukin-12 Activity Improves Myocardial and Vascular Function Compared With Tumor Necrosis Factor-a Antagonism or Cyclosporine in Psoriasis.
    Ikonomidis I; Papadavid E; Makavos G; Andreadou I; Varoudi M; Gravanis K; Theodoropoulos K; Pavlidis G; Triantafyllidi H; Moutsatsou P; Panagiotou C; Parissis J; Iliodromitis E; Lekakis J; Rigopoulos D
    Circ Cardiovasc Imaging; 2017 Sep; 10(9):. PubMed ID: 28899951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Efficiency of Topical Calcipotriol/Betamethasone Treatment in Psoriasis Relies on Suppression of the Inflammatory TNFα - IL-23 - IL-17 Axis.
    Kubin ME; Kokkonen N; Palatsi R; Hägg PM; Väyrynen JP; Glumoff V; Haapasaari KM; Hurskainen T; Tasanen K
    Acta Derm Venereol; 2017 Apr; 97(4):449-455. PubMed ID: 27868150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.